Treatment with 20 and 40 μM fisetin markedly reduced tyrosinase activity in melanoma and α-MSH-stimulated melanoma cells, showing approximately a 50-fold decrease compared with their respective control groups (Figure 2A). Here, STAMBP is linked to melanoma.